ClinicalTrials.gg
RecruitingNCT04608630BoneZoneUpdated Mar 4, 2026

Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults

A Phase 2 interventional study of Denosumab 60 MG/ML and Zoledronic Acid 5Mg/Bag 100Ml Inj in Critical Illness and Osteoporosis, sponsored by Australian and New Zealand Intensive Care Research Centre. Recruiting at 22 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-03-04.

Primary conditionOsteoporosisRegistry: Critical IllnessReclassifiedWhy we changed it
Registry
Critical Illness — the first condition term the registry derived for this study.
ClinicalTrials.gg
Osteoporosis
Why
  1. Critical Illness is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Osteoporosis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Australian and New Zealand Intensive Care Research Centre · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2021; still recruiting 5 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies testing denosumab in Osteoporosis — 8 open to participants now, 11 under way, 2 of them phase 3. Denosumab · Osteoporosis.

Planned enrollment
9th of 64
450 · median 90
Started
2021
with 3 others
Phase 2
14 of 64
1 open now
Primary completion
2027-02
later than 5 of 10 live
Registered
50th of 64
by date

Among the 64 studies testing denosumab in Osteoporosis, this one is the 9th largest by planned enrollment, is one of 4 that started in 2021, is one of 14 in phase 2, reaches primary completion later than 5 of the 10 other live ones, and was the 50th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

8 of the 64 studies testing denosumab in Osteoporosis are open now, in 8 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing denosumab in Osteoporosis, or all of them as a file.
02

Study summary

The Bone Zone trial is a prospective, multi-centre, double-blind, phase II, randomised controlled trial evaluating the effect of denosumab or zoledronic acid compared to placebo on change in bone mineral density over one year in women aged 50 years or older and men aged 70 years or older requiring admission to intensive care for greater than 24 hours.

450 women aged 50 years or older and men aged 70 years or older, admitted to intensive care for greater than 24 hours will be recruited into the study from participating study centres.

Read the detailed description

Intensive care patients face health issues that extend beyond their critical illness. A specific area where critical illness may adversely affect the well-being of survivors is increased bone turnover during critical illness, and accelerated bone loss in subsequent years. Critical illness bone loss begins in the first days of critical illness, occurs in both men and women, and is greatest in post-menopausal women. Loss of bone mineral density is significantly greater at both the femur (-2+4.0% vs -0.7+1.1%, p=0.001) and spine (-2.9+4.1% vs -0.2+1.1%, p\<0.001) in women in the year after critical illness compared to age-matched controls. One year after critical illness, 80% of women aged 50-years or greater are classified as osteoporotic or osteopaenic, compared to 71% of the approximately 3.7 million Australian women aged 50 year or greater. In the year after ICU admission a decrease in femur BMD of -1.52% (+ 2.85) is reported in men, which is significantly higher than age adjusted population controls (-0.42% + 1.13, diff -1.10% (95% CI -1.71 to -0.49, p\<0.001). The annual incidence of first fracture in men aged 70 years and over is similar to the annual incidence of fracture in women aged 50 years and over. In addition, there is a dramatic increase in hip fractures as a proportion of all fracture's males aged 70 years and older in the general population. This population is most likely to suffer the major consequence of accelerated bone loss, fragility fracture, and the associated morbidity, loss of quality of life, and economic cost. Older women who survive critical illness have a significantly higher fragility fracture rate compared to community age-matched controls (Intensive Care Unit 4.33 vs control 2.81 per 100 patient years, adj HR 1.7 (95% CI 1.1-2.5), p=0.02).

Bone antiresorptive therapies are effective at reducing bone loss and decreasing fracture risk in non-critically ill populations. Zoledronic acid and denosumab represent antiresorptive agents with established efficacy in adults, and are potential target interventions able to be delivered during critical illness. Denosumab is a human monoclonal antibody directed against Receptor activator of nuclear factor kappa-Β ligand, a central stimulator of osteoclast activity, and is effective for prevention of fractures and bone loss in osteoporosis and malignancy. Zoledronic acid is a bisphosphonate class agent that binds to bone and suppresses bone resorption by entering osteoclasts and inhibiting the enzyme farnesyl pyrophosphate synthase, resulting in disruption of osteoclast attachment to bone surface. In addition to skeletal effects, there are possible mortality benefits associated with the use of antiresorptive medications in populations with increased bone loss.

There is currently insufficient high-quality evidence to support routine, early use of antiresorptive medications in critically ill adults. The Bone Zone trial is a phase III multi-centre randomised placebo-controlled trial of 450 women aged 50-years or greater and men aged 70-years or greater requiring intensive care admission for more than 2 calendar days, to determine the effect of denosumab or zoledronic acid on the prevention of bone loss in the year after critical illness.

03

Conditions studied

  • Critical Illness
  • Osteoporosis

Browse trials for

Keywords

  • Intensive Care Unit
  • Osteoporosis
  • Bone densitometry
  • Zoledronic acid
  • Denosumab
04

In context

Osteoporosis Reclassified

1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.

This study's planned enrollment of 450 is above the median of 88 across 1,084 interventional studies indexed under Osteoporosis.

Browse Osteoporosis studies →

Lead sponsor

Australian and New Zealand Intensive Care Research Centre is the lead sponsor of 49 studies on the registry; 16 are open to participants now.

Compared within Osteoporosis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Critical Illness. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female age ≥ 50 years or male age ≥ 70 years
  • Has been in the Intensive Care Unit for 2 or more calendar days and is not expected to be discharged from the Intensive Care Unit on the second day
  • Has required Intensive Care Unit level support (i.e. intravenous vasoactive drugs, or invasive mechanical ventilation, or non-invasive ventilation or high flow nasal oxygen at Fraction inspired Oxygen ≥0.4 and/or gas flows ≥40L/m) for a minimum cumulative duration of 6 hours
  • Expected to survive the current hospital admission

Exclusion criteria

Exclusion Criteria:

  • Cancer related bone disease or multiple myeloma
  • Paget's disease
  • Pregnancy
  • Current estimated \<30ml/min or receiving renal replacement therapy
  • Known to denosumab or zoledronic acid
  • Obvious holes in teeth or broken teeth or dental or gum infection
  • Known untreated hypoparathyroidism
  • Current treatment with anti-fracture agent (bisphosphonate, strontium or teriparatide within previous 2 years, or menopausal hormone therapy or romosozumab within previous 12-months or denosumab within previous 6 months)
  • Current fragility fracture of hip, spine, femur or forearm
  • Exceeds weight limit for BMD scan at site or unable to undertake Bone Mineral Density for any reason
  • > 3.0 or count \< 30 10\^9/L
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
450 participants (estimated)

Study arms

  • Active comparator
    Denosumab

    Patients allocated to the Denosumab arm will receive Denosumab 60mg in 1ml, administered via subcutaneous injection on Study Days 1 and 180.

    Drug: Denosumab 60 MG/ML · Drug: Sodium Chloride 0.9% or 5% Dextrose Intravenous

  • Active comparator
    Zoledronic acid

    Patients allocated to the Zoledronic acid arm will receive Zoledronic acid 5mg in 100ml 0.9% Sodium Chloride or 5% Dextrose, administered via intravenous infusion over at least 15 minutes on Study Day 1.

    Drug: Zoledronic Acid 5Mg/Bag 100Ml Inj · Drug: Sodium Chloride 0.9% Injection

  • Placebo comparator
    Placebo

    Patients allocated to the placebo arm will receive 0.9% Sodium Chloride 1ml administered via subcutaneous injection on Days 1 and Day 180 and 0.9% Sodium Chloride 100ml or 5% Dextrose administered via intravenous infusion over at least 15 minutes on Day 1.

    Drug: Sodium Chloride 0.9% or 5% Dextrose Intravenous · Drug: Sodium Chloride 0.9% Injection

Interventions

  • DrugDenosumab 60 MG/ML

    Drug page: DenosumabStudies of DenosumabDenosumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients allocated to the Denosumab arm will receive Denosumab 60mg in 1ml, administered via subcutaneous injection on Study Days 1 and 180.

    Also known as: Prolia, Xgeva

  • DrugZoledronic Acid 5Mg/Bag 100Ml Inj

    Drug page: Zoledronic AcidStudies of Zoledronic AcidZoledronic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients allocated to the Zoledronic acid arm will receive Zoledronic acid 5mg in 100ml 0.9% Sodium Chloride or 5% Dextrose, administered via intravenous infusion over at least 15 minutes on Study Day 1.

    Also known as: Zometa, Reclast, Aclasta

  • DrugSodium ChlorideStudies of Sodium ChlorideSodium Chloride pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients allocated to the placebo arm and Denosumab arm will receive 0.9% Sodium Chloride or 5% Dextrose 100ml administered via intravenous infusion over at least 15 minutes on Day 1.

    Also known as: Saline, Placebo

  • DrugSodium ChlorideStudies of Sodium ChlorideSodium Chloride pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients allocated to the placebo arm and Zoledronic acid arm will receive 0.9% Sodium Chloride 1ml administered via subcutaneous injection on Days 1 and Day 180

    Also known as: Saline, Placebo

07

What researchers measure

Primary outcomes

  1. Annualised change in femoral neck bone mineral density for the year after Intensive Care discharge

    Change in femoral neck bone mineral density T-score between baseline and 12 months

    Time frame: 12 months

Secondary outcomes

  1. Annualised change in lumbar spine bone mineral density for the year after Intensive Care discharge

    Change in lumbar spine bone mineral densityT-score between baseline and 12 months

    Time frame: 12 months

  2. Clinical fragility fracture

    Self-reported incident clinical fractures obtained at follow-up visits. Information on the date, site, and circumstance of the fracture obtained by interview and X-ray report sought and confirmed by medical report.

    Time frame: 6 and 12 months

  3. Vertebral fracture

    Incident vertebral fracture obtained during lateral BMD study

    Time frame: 12 months

  4. Falls

    Self-reported falls incidence and frequency

    Time frame: 6 and 12 months

  5. Hospital readmission

    All hospital readmissions within 12 months will be recorded

    Time frame: 12 months

  6. Mortality

    All deaths from enrolment to 12 months will be recorded

    Time frame: 12 months

  7. Change in quality of life

    Quality of life will be measured using the European Quality of Life scale using a descriptive system scale from 1 to 5

    Time frame: 0, 6 and 12 months.

  8. Bone turnover outcomes (nested sub-study)

    Change in the bone turnover markers serum collagen type 1 cross-linked c-telopeptide (CTX), and serum type 1 procollagen N-terminal propeptide (P1NP)

    Time frame: Day 0, Day 7, 6 and 12 months

08

Study locations

20 of 22 sites recruiting
09

References and documents

Individual participant data

Plan to share: Yes — At the conclusion of the study, the study management committee will consider requests from researchers who provide a methodologically sound scientific proposal as per the Data Sharing Policy set out in the ANZIC Research Centre Terms of Reference.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: As per the ANZIC Research Centre Data Sharing Policy

Access criteria: As per the ANZIC Research Centre Data Sharing Policy

Data sharing details ↗ · www.monash.edu

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2021 (actual). Primary completion is estimated for Feb 2027, 67 months after the start.

Of 33 non-industry phase 2 interventional studies under Osteoporosis, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 65. This study's planned 67 months is above that.

Counting every sponsor, half of 42 studies reached it within 47 months; a quarter within 29 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2020
First posted
Oct 29, 2020
StartActual
Jul 15, 2021
Primary completionEst.
Feb 28, 2027
CompletionEst.
Feb 28, 2027
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04608630
Lead sponsor
Australian and New Zealand Intensive Care Research Centre
Responsible party
Sponsor
First posted
Oct 29, 2020
Start date
Jul 15, 2021
Primary completion
Feb 28, 2027 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Mar 4, 2026

Study contacts

Allison Bone
Contact
allison.bone@monash.edu
+61 3 9903 0343
Tony Trapani
Contact
tony.trapani@monash.edu
+61 3 9903 0343
Neil Orford, A/Prof
study chair · Barwon Health; ANZIC Research Centre
Priya Nair, A/Prof
study chair · St Vincent's Health Sydney

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Denosumab · Zoledronic Acid

Start the discussion